Dexcom (DXCM) Depreciation & Amortization (CF) (2010 - 2026)

Dexcom (DXCM) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $67.1 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $67.1 million, up 11.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $258.9 million (up 14.96% YoY), and the FY2025 annual result was $251.8 million, up 15.66% from the prior year.
• Depreciation & Amortization (CF) rose to $67.1 million in Q1 2026 per DXCM's latest filing, from $65.2 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $67.1 million in Q1 2026 and troughed at $36.3 million in Q4 2022.
• A 5-year average of $51.7 million and a median of $52.5 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) soared 85.53% in 2022, then grew 0.23% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $36.3 million in 2022, then soared by 44.63% to $52.5 million in 2023, then rose by 10.1% to $57.8 million in 2024, then gained by 12.8% to $65.2 million in 2025, then advanced by 2.91% to $67.1 million in 2026.
• Business Quant data shows DXCM's Depreciation & Amortization (CF) at $67.1 million in Q1 2026, $65.2 million in Q4 2025, and $63.6 million in Q3 2025.